Phase I/II Trial of MGCD516 Combined With Nivolumab in Patients With Advanced Clear Cell Renal Cell Cancer That Progressed on Prior VEGF-Targeted Therapy
Phase of Trial: Phase I/II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs Nivolumab (Primary) ; Sitravatinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 24 Apr 2017 Planned End Date changed from 1 Jul 2023 to 1 Apr 2023.
- 24 Apr 2017 Planned primary completion date changed from 1 Jul 2023 to 1 Apr 2023.
- 24 Apr 2017 Status changed from not yet recruiting to recruiting.